[ad_1]
Company Background :
Gufic Biosciences Ltd (NS:) started its plant biotechnology operation recently a few years back to produce and supply the high-yielding and elite planting material of medicinal and other herbal plants using tissue culture techniques. The first biotechnology product was bixa, a source of natural food colour, for which the company has to buy back arrangements with the farmers. This company has a well-developed tissue culture facility for the production of 5 million plants per annum.
The production unit is made by state-of-the-art technology with six growth rooms, which can house 160000 culture bottles at a time. In the inoculation area, 30 persons can work in one shift. The air-conditioning and air handling system incorporates 5 micron and 0.5-micron filters and is designed for class 10,000 and class 100,000 as per us federal standards 209b. The workstations are however class 100.
The company has two greenhouses of 800 square meters with evaporative cooling, misting, and shading equipment for the hardening of tissue culture plants. In addition, the company has shade houses for the hardening of plants at 4 locations.
With the expertise created in the field of agriculture, over the years, along with the right type of research, Gufic has entered into hybrid vegetable seeds. Gufic seeds deals in all major vegetable seeds namely, tomato, chili, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber, and watermelon. It is bringing out varieties/hybrids as per the local demands and preferences for particular characteristics in a crop.
Towards this goal, Gufic seeds have already made arrangements with world-class breeders and companies to get excellent seed material for development and promotions. The company commands the association of skilled, accomplished, and seasoned professionals in research, production, and marketing, and we shall be striving to bring to you the best of hybrids and varieties to suit specific requirements continuously.
Quarterly Results – 09 Feb 2022
The company’s total revenue for the quarter ended December 2021 saw a slight change in the total revenue, having registered total revenue of Rs. 1720.65 millions. The company has announced a 36.01% increase in its profits to Rs. 210.34 millions for the quarter ended December 2021 compared to Rs. 154.65 millions in the corresponding quarter in the previous year. The company reported a good operating profit of 342.49 millions compared to 274.55 millions in the corresponding previous quarter.
Our conclusion:
- Formation / Incorporation of a Wholly Owned Subsidiary of the Company in the United Kingdom (UK) and Ireland will expand the business opportunities of the Company and get several product registrations in its name in the whole of UK and Europe, respectively.
- We expect the stock to witnesses some profit booking @ current levels due to the bull run in stock prices since the last few years/months.
- In the long run, the company has the potential to deliver good returns as it can even cross the 52 Week yearly high in coming quarters.
Disclaimer: The above article is for self-educational purposes. Research conducted by my students for learning purposes.
“Investing involves substantial risk. Neither the author nor the publisher, nor any of their respective affiliates makes any guarantee or other promise as to any result that may be obtained from using the research/report. While past performance may be analyzed in the research, past performance should not be considered indicative of future performance. No reader should make any investment decision without first consulting his or her own personal financial and/or investment advisor and conducting his or her research and due diligence, including carefully considering whether it is suitable for your particular circumstances, as this research/report does not take into account your particular investment objectives, financial situation or needs and is not intended as recommendation appropriate for you. In the event, any information, commentary, analysis, opinions, advice, and/or recommendations in the research/report prove to be inaccurate, incomplete, or unreliable or result in any investment or other losses, the author, the publisher, and their respective affiliates disclaim any and all liability to the maximum extent permitted by law.”
[ad_2]
Source link
